UB Paderborn / Katalog / Suche / in CDI

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

Nature Medicine, 2011-05, Vol.17 (5), p.589-595

2011

Link zum Volltext

Verfügbarkeit prüfen

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

Gastroenterology (New York, N.Y. 1943), 2019-06, Vol.156 (8), p.2313-2329.e7

2019

Link zum Volltext

Verfügbarkeit prüfen

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003―2007)

Antiviral therapy, 2012, Vol.17 (1), p.101-110

2012

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents

PLoS pathogens, 2014-05, Vol.10 (5), p.e1004128-e1004128

2014

Link zum Volltext

Verfügbarkeit prüfen

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C

Gut, 2015-03, Vol.64 (3), p.483-494

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial

Clinical and translational gastroenterology, 2022-06, Vol.13 (6), p.e00492

2022

Link zum Volltext

Verfügbarkeit prüfen

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation

The Journal of experimental medicine, 2010-08, Vol.207 (9), p.2019-2031

2010

Link zum Volltext

Verfügbarkeit prüfen

Interleukin‐32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance

Hepatology communications, 2019-09, Vol.3 (9), p.1205-1220

2019

Link zum Volltext

Verfügbarkeit prüfen

Loss of hepatitis B surface antigen in a real‐life clinical cohort of patients with chronic hepatitis B virus infection

Liver international, 2015-01, Vol.35 (1), p.130-139

2015

Link zum Volltext

Verfügbarkeit prüfen

Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies

Gastroenterology (New York, N.Y. 1943), 2012-07, Vol.143 (1), p.223-233.e9

2012

Link zum Volltext

Verfügbarkeit prüfen

A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C

Gastroenterology (New York, N.Y. 1943), 2011-09, Vol.141 (3), p.890-899.e4

2011

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis B virus mutations potentially conferring adefovir/ tenofovir resistance in treatment-naive patients

World journal of gastroenterology : WJG, 2009-02, Vol.15 (6), p.753-755

2009

Link zum Volltext

Verfügbarkeit prüfen

Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks

PloS one, 2013-06, Vol.8 (6), p.e67254

2013

Link zum Volltext

Verfügbarkeit prüfen

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease

Oncotarget, 2017-09, Vol.8 (38), p.62842-62857

2017

Link zum Volltext

Verfügbarkeit prüfen

Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81

Hepatology (Baltimore, Md.), 2007-12, Vol.46 (6), p.1722-1731

2007

Link zum Volltext

Verfügbarkeit prüfen

Neutralizing Host Responses in Hepatitis C Virus Infection Target Viral Entry at Postbinding Steps and Membrane Fusion

Gastroenterology (New York, N.Y. 1943), 2008-11, Vol.135 (5), p.1719-1728.e1

2008

Link zum Volltext

Verfügbarkeit prüfen

Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis

Acta diabetologica, 2014, Vol.51 (3), p.455-460

2014

Link zum Volltext

Verfügbarkeit prüfen

Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection

Expert opinion on investigational drugs, 2013-11, Vol.22 (7), p.853-862

2013

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization

The Journal of infectious diseases, 2013-04, Vol.207 (8), p.1306-1315

2013

Link zum Volltext

Verfügbarkeit prüfen

An unusual cause of abdominal pain

Acta gastro-enterologica belgica, 2013-06, Vol.76 (2), p.261

2013

Link zum Volltext

Verfügbarkeit prüfen

Neutralizing antibodies in hepatitis C virus infection

World journal of gastroenterology : WJG, 2007-09, Vol.13 (36), p.4824

2007

Link zum Volltext

Verfügbarkeit prüfen

Frequent Compartmentalization of Hepatitis C Virus with Leukocyte-Related Amino Acids in the Setting of Liver Transplantation

The Journal of infectious diseases, 2008-12, Vol.198 (11), p.1656-1666

2008

Link zum Volltext

Verfügbarkeit prüfen

Boceprevir and personalized medicine in hepatitis C virus infection

Pharmacogenomics and personalized medicine, 2012-01, Vol.5, p.125-137

2012

Link zum Volltext

Verfügbarkeit prüfen

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents: e1004128

PLoS pathogens, 2014-05, Vol.10 (5)

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003―2007)

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C

Safety and Antiviral Activity of EGFR Inhibition by Erlotinib in Chronic Hepatitis C Patients: A Phase Ib Randomized Controlled Trial

Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation

Interleukin‐32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance

Loss of hepatitis B surface antigen in a real‐life clinical cohort of patients with chronic hepatitis B virus infection

Mutations That Alter Use of Hepatitis C Virus Cell Entry Factors Mediate Escape From Neutralizing Antibodies

A Poxvirus Vaccine Is Safe, Induces T-Cell Responses, and Decreases Viral Load in Patients With Chronic Hepatitis C

Hepatitis B virus mutations potentially conferring adefovir/ tenofovir resistance in treatment-naive patients

Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease

Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy

Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81

Neutralizing Host Responses in Hepatitis C Virus Infection Target Viral Entry at Postbinding Steps and Membrane Fusion

Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis

Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection

Hepatitis C Virus Envelope Glycoprotein Signatures Are Associated With Treatment Failure and Modulation of Viral Entry and Neutralization

An unusual cause of abdominal pain

Neutralizing antibodies in hepatitis C virus infection

Frequent Compartmentalization of Hepatitis C Virus with Leukocyte-Related Amino Acids in the Setting of Liver Transplantation

Boceprevir and personalized medicine in hepatitis C virus infection

Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents: e1004128

Suchergebnisse filtern